REFERENCES

1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. The Lancet.2017;390:946-958.
2. Saravanos GL, Sheel M, Homaira N, et al. Respiratory syncytial virus-associated hospitalisations in Australia, 2006–2015. Med J Aust. 2019;210:447-453.
3. Kusel MM, Kebadze T, Johnston SL, Holt PG, Sly PD. Febrile respiratory illnesses in infancy & atopy are risk factors for persistent asthma & wheeze. Eur Respir J. 2012;39:876-882.
4. Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol.2017;140:895-906.
5. Driscoll A, Arshad S, Bont L, et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting.Vaccine. 2020;38:2435–2448.
6. Stensballe LG, Brunbjerg Simonsen J, Thomsen SF, et al. The causal direction in the association between respiratory syncytial virus hospitalization and asthma. J Allergy Clin Immunol.2009;123:131-137.e131.
7. Muňoz FM, Swamy GK, Hickman SP, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. 2019;220:1802-1815.
8. Kong K, Krishnaswamy S, Giles M. Maternal vaccinations. Aust J Gen Pract. 2020;49:630-635.
9. Madhi SA, Polack FP, Piedra PA, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020;383:426-439.
10. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. .Pediatrics. 1998;102:531-537.
11. Griffin MP, Yuan Y, Takas T, et al. Single-dose Nirsevimab for prevention of RSV in preterm infants. N Engl J Med.2020;383:415-425.
12. Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J. 2008;27:207-212.
13. Chu HY, Steinhoff MC, Magaret A, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis. 2014;210:1582-1589.
14. Saso A, Kampmann B. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? Lancet Infect Dis. 2016;16:e153-e163.
15. Edwards KM. Maternal antibodies and infant immune responses to vaccines. Vaccine. 2015;33:6469-6472.
16. Trento A, Rodríguez-Fernández R, González-Sánchez MI, et al. The complexity of antibody responses elicited against the respiratory syncytial virus glycoproteins in hospitalized children younger than 2 years. Front Microbiol. 2017;8:1-12.
17. O’Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15:1398-1408.
18. Scheltema NM, Nibbelke EE, Pouw J, et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: A randomised controlled trial. Lancet Respir Med. 2018;6:257-264.
19. Nyiro JU, Kombe IK, Sande CJ, et al. Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya. PLoS One. 2017;12:e0177803.
20. Scheltema NM, Kavelaars XM, Thorburn K, et al. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy. Vaccine. 2018;36:4693-4700.
21. Kusel MM, de Klerk NH, Holt PG, Kebadze T, Johnston SL, Sly PD. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J. 2006;25:680-686.
22. Lambert SB, Ware RS, Cook AL, et al. Observational research in childhood infectious diseases (ORChID): A dynamic birth cohort study.BMJ Open. 2012;2:e002134.
23. Sarna M, Lambert SB, Sloots TP, et al. Viruses causing lower respiratory symptoms in young children: findings from the ORChID birth cohort. Thorax. 2018;73:969-979.
24. Sarna M, Ware RS, Lambert SB, Sloots TP, Nissen MD, Grimwood K. Timing of first respiratory virus detections in infants: A community-based birth cohort study. J Infect Dis.2018;217:418-427.
25. Sly PD, Cormier SA, Lomnicki S, Harding JN, Grimwood K. Environmentally persistent free radicals: Linking air pollution and poor respiratory health? Am J Respir Crit Care Med.2019;200:1062-1063.
26. Sarna M, Ware RS, Sloots TP, Nissen MD, Grimwood K, Lambert SB. The burden of community-managed acute respiratory infections in the first 2-years of life. Pediatr Pulmonol. 2016;51:1336-1346.
27. Takashima MD, Grimwood K, Sly PD, et al. Epidemiology of respiratory syncytial virus in a community birth cohort of infants in the first 2 years of life. Eur J Pediatr. 2021;180:2125-2135.
28. Hallak LK, Collins PL, Knudson W, Peeples ME. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology.2000;271:264-275.
29. Stensballe LG, Ravn H, Kristensen K, Meakins T, Aaby P, Simoes EA. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr. 2009;154:296-298.
30. Piedra PA, Jewell AM, Cron SG, Atmar RL, Paul Glezen W. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine.2003;21:3479-3482.
31. Buchwald AG, Graham BS, Traore A, et al. Respiratory syncytial virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life. Clin Infect Dis. 2020;ciaa648.
32. Nyiro JU, Sande CJ, Mutunga M, et al. Absence of association between cord specific antibody levels and severe respiratory syncytial virus (RSV) disease in early infants: A case control study from Coastal Kenya.PLoS One. 2016;11:e0166706.
33. Singleton RJ, Bruden D, Bulkow LR. Respiratory syncytial virus season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta.Pediatr Infect Dis J. 2007;26:S46-50.
34. Chu HY, Tielsch J, Katz J, et al. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. J Clin Virol.2017;95:90-95.
35. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol.2009;123:398-403.
36. Habibi MS, Jozwik A, Makris S, et al. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015;191:1040-1049.
37. Brady MT, Byington CL, Davies HD, et al. Updated guidance for Palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus Infection.Pediatrics 2014;134:415-420.
38. Brunwasser SM, Snyder BM, Driscoll AJ, et al. Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis. Lancet Respir.2020;8:795-806.
39. National Asthma Council Australia. Australian Asthma Handbook, Version 2.0. . In:2019: http://www.asthmahandbook.org.au. Accessed 23 April, 2020.
40. Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory syncytial virus vaccines. Pediatr Infect Dis J.2019;38:e266-e269.